Navigation Links
ASEBIO Requests the Alignment of Spain With the European Union's Future Strategy of Bioeconomy
Date:9/29/2010

ASEBIO Requests the Alignment of Spain With the European Union's Future Strategy... -- PAMPLONA, Spain, September 29, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

ASEBIO Requests the Alignment of Spain With the European Union's Future Strategy of Bioeconomy

 

PAMPLONA, Spain, September 29, 2010 /PRNewswire/ -- The figures regarding BioSpain 2010 have beaten all previous records, to the extent that it has become the most important event in biotechnology in southern Europe. "Investment in Biotechnology and in R&D+i is crucial in order to prevent our best researchers from moving abroad", warned Jose Maria Fernandez Sousa, president of ASEBIO (Spanish Association.of Biocompanies), during the press conference held to present BioSpain 2010. "Navarre is greatly encouraging these two aspects and proof of this is the enormous interest it has shown in the organisation of this event". In addition, this autonomous government is creating a fund of 500 million euros to invest in this field which has a very promising future.

The most prominent feature of BioSpain 2010 is that of its internationalisation, so necessary for these kinds of companies. In this edition there are a total of 160 companies in 132 stands. Likewise, it is expected that there will be over 2,000 business meetings between approximately 600 companies and organisations, of which 150 are from outside Spain. "Brussels is aware of the importance of biotechnology for Europe's future, which is why it has announced a bioeconomy strategy that has yet to be defined by the European Union", explained Fernandez Sousa. In this context, it is estimated that the biotechnology sector will represent 2.7% of GDP in OECD countries, which is why ASEBIO considers that it would be good for Spain to implement the same strategy.

At the Investor's Forum 30 biotechnology projects have been selected, which will be explained during the congress. The president of ASEBIO recommended that our companies make themselves known internationally in order to attract funding from outside Spain. To achieve this, it is essential that Spanish biotechnology companies participate in the most important international fairs.

Tumour stem cells

The first plenary conference was given by Carlos Cordon-Cardo, from the University of Columbia, who spoke about tumour stem cells. "If we do not understand the origin of cancer, we will not be able to understand its final chapters", he said. According to the lecture, "the most effective strategy is that of identifying these cells in tumours and metastases to then attack them", he explained. In this regard, the identification of these stem cells "could have important clinical applications concerning the prognosis of the disease".

Lucia Cecilia Mercado lcecilia@asebio.com tel: +34-91-210-93-74
'/>"/>

SOURCE Asebio
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug"
2. GeoVax Labs Requests pre-IND Meeting With FDA
3. Stemedica Requests Pre-IND Meeting With FDA
4. The West Michigan Science & Technology Initiative is Named Statewide Reviewer for Life Science Funding Requests Through New Program
5. Xmark Requests That Icagen Oust Its CEO and Pursue Strategic Alternatives, and Calls on Board Members to Resign
6. Biotechnology Value Fund, L.P. Requests Avigen Board to Provide Critical Information to Stockholders
7. deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter
8. Palatin Announces Strategic Realignment of Operations
9. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
10. AMDL, Inc. Announces Strategic Realignment
11. BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)...  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company ... autoimmune diseases, asthma and allergic diseases and cancer, ... and full year ended December 31, 2016 and ... and clinical highlights. "During 2016, we ... by starting five clinical trials across our XmAb ...
(Date:2/28/2017)... ... February 28, 2017 , ... FireflySci is a small cuvette manufacturer ... late 2014, FFS had a mission to bring affordable and quality lab equipment to ... product that gives a lab everything needed to get started with using cuvettes. , ...
(Date:2/28/2017)... ... February 28, 2017 , ... ACEA Biosciences, a pioneer in cell analysis instrumentation ... Dr. Roger (Feng) Luo as the new Vice President of Global Clinical Development. ... drug companies, Dr. Luo will now team with Dr. Li Xu, Chief Medical Officer, ...
(Date:2/28/2017)... ... February 28, 2017 , ... GigaGen ... from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc. ... to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology ...
Breaking Biology Technology:
(Date:2/3/2017)... 2017 A new independent identity strategy consultancy ... (IdSP) . Designed to fill a critical niche in ... founding partners Mark Crego and Janice ... in identity expertise that span federal governments, the 9/11 ... Crego-Kephart combined expertise has a common theme born from ...
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
(Date:1/24/2017)... YORK , Jan. 24, 2017 ... study of the laboratory use of nuclear magnetic ... 363 experienced end-users and profiled current practices, developments, ... years, as well as growth and opportunities. These ... Instrument suppliers, NMR instruments, needs and innovation requirements, ...
Breaking Biology News(10 mins):